Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-06 · 399 (9) · 13661-13676
DOI: 10.1007/s00210-026-05233-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 30.03.2026. Verfasst von Lifeng Dan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China. Hauptthemen laut MEDLINE: Sirolimus, Adverse Drug Reaction Reporting Systems, MTOR Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing, China; MSC-exosome was used to study the interaction between TGF-β and Wnt signaling pathway in chronic allograft neph…, The doctoral program of the first affiliated hospital of Chongqing Medical University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.
- Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China. sushuai930809@163.com.
- Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China. yinzhikang2005@sina.com.
Förderung
- Natural Science Foundation of Chongqing, China; MSC-exosome was used to study the interaction between TGF-β and Wnt signaling pathway in chronic allograft neph…
- The doctoral program of the first affiliated hospital of Chongqing Medical University
Zitieren
APA
Dan, L., Liu, Z., Zhao, Z., Ran, Y., Zhou, J., Li, D., Zhou, R., Su, S., & Yin, Z. (2026). Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(9), 13661-13676. https://doi.org/10.1007/s00210-026-05233-9
Vancouver
Dan L, Liu Z, Zhao Z, Ran Y, Zhou J, Li D, et al. Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(9):13661-13676. doi:10.1007/s00210-026-05233-9
BibTeX
@article{Dan2026,
author = {Dan, Lifeng and Liu, Zhenyu and Zhao, Zecang and Ran, Yueli and Zhou, Jiangtao and Li, Dongyang and Zhou, Renjie and Su, Shuai and Yin, Zhikang},
title = {Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {9},
pages = {13661--13676},
doi = {10.1007/s00210-026-05233-9}
}
EUVIMED